SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action

Group 1 - A class action has been filed against Sage Therapeutics, Inc. on behalf of investors who purchased securities between April 12, 2021, and July 23, 2024 [1][2] - The allegations include that Sage Therapeutics misled investors regarding the efficacy of its drugs, specifically zuranolone, SAGE-718, and SAGE-324, which were claimed to be less effective than represented [2] - The complaint states that the company's public statements were materially false and misleading, affecting the perceived clinical, regulatory, and commercial prospects of its products [2] Group 2 - Shareholders interested in serving as lead plaintiff must submit their application by October 28, 2024, and can choose to remain absent class members without participating in the case [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless the case is won [4] - Robbins LLP has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5]